Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lannett, a US based developer of generic pharmaceutical products, has started supplying Morphine Sulfate Oral Solution product.
Subscribe to our email newsletter
The supplying of the product follows approval from the US Food and Drug Administration (FDA) its 505(b)(2) new drug application (NDA).
Lannett president and CEO Arthur Bedrosian said this is their first drug approval using a 505(b)(2) application.
"We have received orders from drug wholesalers, nursing home providers and distributors," Bedrosian said.